Key safety observations from Phase 2 data include: Gastrointestinal side effects were the most commonly reported adverse events Dose-dependent tolerability issues were noted, particularly at higher doses, with meaningful discontinuation rates Increases in heart rate were observed, consistent with the known class effect of GLP-1 receptor agonists
John Curtis's America 250 walk
It is not known if Wegovy is safe and effective for use for the treatment of MASH in children under 18 years.
Chia YC, Ching SM, Ooi PB, Beh HC, Chew MT, Chung FFL, et al
Connection between weight loss and better sleep Obesity represents the primary modifiable risk factor for obstructive sleep apnea (OSA) 34
Protein from lean sources also promotes GLP-1 release while helping maintain muscle massan important consideration for anyone working on their healthy weight goals